Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Revenue rose to Rs 7,073 crore. Read more. Jan 28, 2025 16:23 Cipla Q3 Net Profit Soars 49% to Rs 1,571 Crore Cipla's net profit surged 49% to Rs 1,571 crore in Q3 FY25, driven by strong revenue ...

Cipla Q3 Results: Pharmaceutical major Cipla on Tuesday reported a 49 per cent year-on-year (YoY) increase in its consolidated net profit for the December quarter (Q3 FY25) at Rs 1,574.6 crore, from ...

That more than made up for a 1% drop in sales in North America, Cipla's second-biggest market, and helped the company's total revenue climb 7.1% to 70.73 billion rupees, surpassing market ...

Do you ever ask yourself why some company logos we see at events get stuck in our heads while others vanish quicker than invisible ink? It’s not magic, and it isn’t luck either. The truth is that they ...

At 09:29am, Cipla was quoting at Rs 1,439.55, down Rs 32.75, or 2.22 percent, on the BSE. The routine current Good Manufacturing Practices (cGMP) inspection at company’s manufacturing facility ...

Drug major Cipla reported a 49% year-on-year jump in its December quarter consolidated net ... which was up 7% over Rs 6,604 crore reported in the corresponding quarter of the previous financial year.

The Listing Page of Cipla Ltd. presents the Incorporation Date, Public Issue Date, Book Closure dates, Face Value, Key Listing information, Indices it is a part of, and the Exchanges where the company ...

The company's revenue climbed 7.1% year-on-year to Rs 7,073 crore, whereas the earnings before interest, taxes, depreciation and amortisation increased by 13.8% to Rs 1,989 crore. The Ebitda margin ...